Ladenburg downgraded Zynerba Pharmaceuticals (ZYNE) to Neutral from Buy without a price target after the company entered into a definitive agreement to be acquired by Harmony Biosciences (HRMY). Under the terms of the agreement, Harmony will commence a tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60M in the aggregate, plus one non-tradeable contingent value right per share, representing the right to receive potential additional payments of up to $140M in the aggregate, subject to the achievement of certain clinical, regulatory and sales milestones.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZYNE:
- Zynerba Pharma (NASDAQ:ZYNE) Skyrockets 3x on Acquisition by Harmony Bio (NASDAQ:HRMY)
- Harmony Biosciences to acquire Zynerba
- HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
- Rising High: Exclusive talk with cannabis market research firm BDSA
- ZYNE Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue